Dr. Bellmunt on Immunotherapy Combination Trials in Bladder Cancer

Joaquim Bellmunt, MD, PhD
Published: Wednesday, Mar 28, 2018



Joaquim Bellmunt, MD, PhD, associate professor of medicine, Harvard Medical School, director, Bladder Cancer Center, Dana-Farber Cancer Institute, discusses trials investigating combinations with immunotherapy for patients with bladder cancer.

There are several other trials combining targeted agents in the second-line setting. These trials are mainly phase II studies, but if there is a signal then perhaps they can jump to a phase III trial in the second-line setting, says Bellmunt.

Immunotherapy drugs are moving to different settings, such as frontline metastatic disease where there are a number of trials with combination immunotherapy agents compared with standard-of-care chemotherapy. Perhaps these trials can change the way that physicians are treating first-line patients with bladder cancer, says Bellmunt.
 
SELECTED
LANGUAGE


Joaquim Bellmunt, MD, PhD, associate professor of medicine, Harvard Medical School, director, Bladder Cancer Center, Dana-Farber Cancer Institute, discusses trials investigating combinations with immunotherapy for patients with bladder cancer.

There are several other trials combining targeted agents in the second-line setting. These trials are mainly phase II studies, but if there is a signal then perhaps they can jump to a phase III trial in the second-line setting, says Bellmunt.

Immunotherapy drugs are moving to different settings, such as frontline metastatic disease where there are a number of trials with combination immunotherapy agents compared with standard-of-care chemotherapy. Perhaps these trials can change the way that physicians are treating first-line patients with bladder cancer, says Bellmunt.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Atlanta: Advances in the Treatment of Chronic Lymphocytic LeukemiaFeb 28, 20190.5
Community Practice Connections™: 2nd Annual International Congress on Immunotherapies in Cancer™: Focus on Practice-Changing ApplicationFeb 28, 20192.0
Publication Bottom Border
Border Publication
x